Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase ...
Sep 11, 2017
0
0
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. (1)
Sep 8, 2017
0
4
The chemotherapy docetaxel is widely accepted as a standard therapy for metastatic castration-resistant prostate cancer. But 10-20 percent of patients will have adverse side effects that force discontinuation of treatment. ...
Aug 5, 2017
0
41
Among patients previously treated for a type of advanced lung cancer, use of a combination treatment did not improve progression-free or overall survival, according to a study published by JAMA.
May 9, 2017
0
0
(HealthDay)—Metformin use in combination with docetaxel chemotherapy does not significantly improve survival in patients with diabetes and metastatic castration-resistant prostate cancer, according to a study published ...
Apr 11, 2017
0
0
Adding an aromatase inhibitor to presurgery treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor ...
Dec 9, 2016
0
0
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. ...
Aug 18, 2016
0
1
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent ...
Jan 11, 2016
0
1
Two papers from UCL show that having early chemotherapy improves survival for men with prostate cancer. The papers, published in the Lancet and Lancet Oncology, report the results from the STAMPEDE clinical trial and a meta-analysis.
Dec 22, 2015
0
2
